AEMPS interface.
The Spanish Agency for Medicines and Health Products (AEMPS) has published four new Therapeutic GPS reports (IPT). Three of them are compatible with oncology medications, while the other is for the secondary macular edema.
This last report is FARICIMAB (VABYSM)Referred to in the treatment of adult patients with visual change due to secondary macular edema to the clogging of the retinal vein.
the Retinal vein (OVR is one of the most common vascular disorders and is associated with visual loss variables. The second cause of blindness in patients with vascular disorders in the retina is behind diabetic retinopathy.
VABYSMO is served in an injection solution with 120 mg/ml of FARICIMAB or in a pre -loaded syringe with the same solution. This medicine He must be managed by a qualified doctor With experience in intravitee injection. The recommended dose for adult treatment with secondary macular edema to OVR is 6 mg (0.05 ml of solution) that is administered by injection inside the base every 4 weeks.
Esophageal, lung and molecular lung cancer treatments
The first cancer drug reports Tesllezome (Tiffra)Referred to treatment in unilateral therapy for adult patients who suffer from healing cell cancer from the non -disk -advanced esophageal or metable, after the previous chemotherapy on the basis of platinum.
Tevimbra was also declared, In conjunction with platinum -based chemotherapy, For the treatment of the first line for CCEE, is developed, locally advanced or metric in adult patients whose tumors express PD-L1 with a positive degree of tumor area.
In one of the articles, this drug showed excellence in a statistically significant way Chemotherapy, Con Docetaxel, Bacltaxel and IrinotecánIn the treatment of advanced, frequent or metastatic CCEE, in patients previously treated with platinum -based chemotherapy, which improves SG in 2.3 months. This result can be considered relevant, according to experts, especially if the general public diagnosis of patients with disabled, frequent, or metastatic patients are taken into consideration.
The report highlights that Esophageal cancer is the most eleventh cancer around the world Regarding its occurrence, 2.6 % of all diagnoses and the seventh repetitive cause of the death of cancer in 2020.
The second report corresponds to Epcoritamab (reaction) As a mono (LF) lymphoma in relapse or thermal lymphocytes after two or more systemic treatment lines.
It is an extension of referring to the treatment of adult patients with LF to the previous indicator in large LBDCG. It was declared on the basis Results of the expansion of non -Hodgkin lymphoma.
Administer Subcutaneous injection (SC), in 28 cycles. The weekly injection therapy begins from the 1 to 3 period, followed by injection every two weeks between the 4 and 9 cycle. From the 10th session, the drug is given every 4 weeks and the treatment must continue until the disease progresses or unacceptable harmful effects occur.
Epcoritamab is authorized to treat adult patients with LF R/R receiving at least 2 previous systemic treatments. Porled lymph nodes LNH lymphoma (LNH) is a slow origin It features a pattern of continuous murderer and is spreading frequently and increasingly short.
It occurs about 5 cases per 100,000 people and the year, which is slightly higher in men compared to women. Average age at diagnosis is about 60 years. The second most popular LNH and the most common lymph in Hodgkin (LNHI), and almost formed. 20 % of all new LNH cases in Western countries.
The latest reports belonging to the oncology medications are those Encouragement (Bravvovi) In partnership with Binimetinib (Mektovi) in the treatment of adult patients with non -microscopic lung cancer (CPNM) advanced with the Braf V600E mutation.
The Enrafeenib/Binimetinib group leads to an increased anti -tumor activity, compared to treatment with any of the drugs individually. Not Osbriente, not available No comparison directly Between Dabrafeenib/Tradeenib and Effenib/Binimetinib group that can appear with solid results the differences in the effectiveness of each of the treatments.
Lung cancer is The first cause of the death of cancer all over the world, With 20.7 % of the total deaths of this cancer in 2022 in Europe. Most cases have diagnostic metastasis and a low survival rate in 5 years.
The information published in the medical writing contains data, data and data from official institutions and health professionals. However, given any questions related to your health, consult the opposite health specialist.
